Idiosyncratic Drug-Induced Liver Injury in a Healthy Patient Following PCSK9-Inhibitor Injection

Overview

Journal Case Reports Hepatol

Publisher Wiley

Specialty Gastroenterology

Date 2024 Jan 22

PMID 38249623

Authors

B-O Stuben

D P Hoyer

S Radunz

F Saner

H Schmidt

H A Baba

J W Treckmann

L I Mazilescu

Affiliations

Soon will be listed here.

Abstract

Background: Acute liver injury is a life-threatening condition with disparate aetiology. Swift and adequate interdisciplinary treatment is essential to assure the best possible outcomes in these patients. Investigations to identify the cause of the condition and the implementation of quick and appropriate treatment can be lifesaving. . In October 2022, an otherwise healthy 66-year-old male presented at the University Hospital Essen with acute liver injury following an inclisiran injection for hypercholesterinaemia. Four weeks following admission, the patient fully recovered after initially receiving short-term cortisol therapy and open albumin (OPAL) dialysis, and the indices of liver, kidney, and coagulation function were normal at discharge.

Conclusion: This is to our knowledge the first reported acute liver injury due to an inclisiran injection. Cortisol in combination with OPAL dialysis is an effective method for the treatment of acute liver injury caused by inclisiran injury, and in this case, it led to a near-complete reversal of the acute liver injury at the time of discharge.

References

Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

Rogula S, Blazejowska E, Gasecka A, Szarpak L, Jaguszewski M, Mazurek T . Inclisiran-Silencing the Cholesterol, Speaking up the Prognosis. J Clin Med. 2021; 10(11). PMC: 8199585. DOI: 10.3390/jcm10112467. View

Dyrbus K, Gasior M, Penson P, Ray K, Banach M . Inclisiran-New hope in the management of lipid disorders?. J Clin Lipidol. 2019; 14(1):16-27. DOI: 10.1016/j.jacl.2019.11.001. View

Teschke R, Danan G . Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM). Diagnostics (Basel). 2021; 11(3). PMC: 7999240. DOI: 10.3390/diagnostics11030458. View

FitzGerald K, White S, Borodovsky A, Bettencourt B, Strahs A, Clausen V . A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. N Engl J Med. 2016; 376(1):41-51. PMC: 5778873. DOI: 10.1056/NEJMoa1609243. View

Wright R, Collins M, Stoekenbroek R, Robson R, Wijngaard P, Landmesser U . Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clin Proc. 2019; 95(1):77-89. DOI: 10.1016/j.mayocp.2019.08.021. View

Wright R, Ray K, Raal F, Kallend D, Jaros M, Koenig W . Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021; 77(9):1182-1193. DOI: 10.1016/j.jacc.2020.12.058. View

Meunier L, Ursic-Bedoya J, Pageaux G, Larrey D . Pantoprazole-induced autoimmune chronic hepatitis. Liver Int. 2018; 38(6):995-999. DOI: 10.1111/liv.13737. View

Sandig C, Flechtenmacher C, Stremmel W, Eisenbach C . Pantoprazole induces severe acute hepatitis. Z Gastroenterol. 2011; 49(2):207-10. DOI: 10.1055/s-0029-1245613. View

10.

Hovingh G, Lepor N, Kallend D, Stoekenbroek R, Wijngaard P, Raal F . Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study. Circulation. 2020; 141(22):1829-1831. DOI: 10.1161/CIRCULATIONAHA.119.044431. View

11.

Aguilar-Salinas C, Gomez-Diaz R, Corral P . New Therapies for Primary Hyperlipidemia. J Clin Endocrinol Metab. 2021; 107(5):1216-1224. DOI: 10.1210/clinem/dgab876. View

12.

Raal F, Kallend D, Ray K, Turner T, Koenig W, Wright R . Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020; 382(16):1520-1530. DOI: 10.1056/NEJMoa1913805. View

13.

Sommerfeld O, Neumann C, Becker J, von Loeffelholz C, Roth J, Kortgen A . Extracorporeal albumin dialysis in critically ill patients with liver failure: Comparison of four different devices-A retrospective analysis. Int J Artif Organs. 2023; 46(8-9):481-491. PMC: 10483887. DOI: 10.1177/03913988231191952. View